Schwandner T, Heimerl T, König I R, Kierer W, Roblick M, Bouchard R, Unglaube T, Holch P, Kolbert G, Padberg W, Ziegler A
Justus-Liebig-Universität Gießen, Klinik für Allgemein-, Viszeral-, Thorax- und Transplantationschirurgie, Gießen, Deutschland.
Zentralbl Chir. 2012 Aug;137(4):345-51. doi: 10.1055/s-0031-1271468. Epub 2011 Sep 27.
The evidence for conservative treatment of anal incontinence is poor. In our first publication [Schwandner et al. Dis Colon Rectum 2010; 53: 1007-1016] we demonstrated that a novel therapeutic concept, termed triple target treatment (3T), combining amplitude-modulated medium frequency stimulation and electromyography biofeedback (EMG-BF) was superior to EMG-BF alone. Questions about the required treatment duration and the relevant subgroups of patients with sphincter damage and damaged anal sensibility were not addressed.
We enrolled 158 patients with anal incontinence in this randomized study. Here, we -report on the important subgroup analyses of patients with and without sphincter damage and damaged anal sensibility for the endpoints Cleveland Clinic Score (CCS) and success record. Using the results of this study we propose a novel treatment algorithm which is open for discussion.
In patients with sphincter damage, the median difference on the CCS from baseline to 9 months was 5 points higher for 3T than for EMG-BF (95 % confidence interval 0-8; p = 0.0168). While 47 % of the patients with sphincter damage became continent with 3T, only 18 % did with EMG-BF (p = 0.0036). Ten of 17 patients in the 3T group regained anal sensibility after 3 months stimulation. There was tendency towards improved continence in patients with neuropathy upon 3T treatment (p = 0.1219).
3T is superior to EMG-BF alone for patients with sphincter damage and neuropathic anal incontinence. It is a successful key element within our treatment algorithm, even in patients with sphincter damage and neuropathic anal incontinence.
肛门失禁保守治疗的证据不足。在我们的第一篇出版物中[施万德纳等人。《直肠肛管疾病》2010年;53: 1007 - 1016],我们证明了一种名为三重目标治疗(3T)的新治疗概念,即将调幅中频刺激与肌电图生物反馈(EMG - BF)相结合,优于单纯的EMG - BF。但关于所需治疗时长以及括约肌损伤和肛门感觉受损患者的相关亚组问题尚未得到解决。
我们在这项随机研究中纳入了158例肛门失禁患者。在此,我们报告了针对克利夫兰诊所评分(CCS)和成功记录终点的有无括约肌损伤及肛门感觉受损患者的重要亚组分析。利用本研究结果,我们提出了一种可供讨论的新治疗算法。
在括约肌损伤患者中,从基线到9个月时,3T组CCS的中位数差异比EMG - BF组高5分(95%置信区间0 - 8;p = 0.0168)。3T组47%的括约肌损伤患者恢复了控便能力,而EMG - BF组只有18%(p = 0.0036)。3T组17例患者中有10例在刺激3个月后恢复了肛门感觉。3T治疗的神经病变患者控便能力有改善趋势(p = 0.1219)。
对于括约肌损伤和神经性肛门失禁患者,3T优于单纯的EMG - BF。它是我们治疗算法中的一个成功关键要素,即使对于括约肌损伤和神经性肛门失禁患者也是如此。